The World Health Organization said on Monday it hoped to conduct a full review by the end of the year of a dengue vaccine that was suspended last week in the Philippines.   The Philippines also ordered an investigation on Monday. On Friday, the department of health halted its dengue immunization program after the manufacturer, French drug company Sanofi Pasteur, announced the vaccine must be strictly limited due to evidence it can worsen dengue in people not previously exposed to the infection.  More than 730,000 children in the Philippines have received the vaccine, commonly known as Dengvaxia. Philippines puts dengue immunization program on hold The WHO has recommended that the vaccine only be used in people who have had a prior dengue infection. The government of Brazil, where dengue is common, confirmed it already had recommended restricted use of the vaccine but had not suspended it entirely. Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila on Monday but did not say why action was not taken after a WHO report in mid-2016 that identified the risk the company was now flagging. Dr Joselito Sta. Ana, Sanofi Pasteur Regional Director, gestures during a media briefing on the dengue vaccine at a hotel in Manila on Monday. Dr. Ruby Dizon, Sanofi's medical director (second from left), says the company is not aware of any deaths related to dengue vaccination. (Romeo Ranoco/Reuters) A non-governmental organization (NGO) said it had received information that three children who were vaccinated with Dengvaxia in the Philippines had died and a senator said he was aware of two cases. However, Department of Health Undersecretary Gerardo Bayugo told Reuters the three referred to by the NGO died due to causes not related to the vaccine and Sanofi said no deaths had been reported as a result of the program. "As far as we know, as far as we are made aware, there are no reported deaths that are related to dengue vaccination," said Ruby Dizon, medical director at Sanofi Pasteur Philippines. In a statement, Sanofi said the long-term safety evaluation of the vaccines showed significantly fewer hospitalizations due to dengue in